The short version of dual agonist fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-19. Anything still debated is marked as such rather than presented as settled.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Visual inspection serves only as a preliminary check |
| Solubility | Freely soluble in water and aqueous buffers | Gentle mixing may be needed to reach full dissolution |
| Typical storage | Minus 20 degrees Celsius or colder, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Primary analytical method | Reversed-phase HPLC with mass detection | Purity reported as chromatographic area percent |
| Common synonyms | GIP/GLP-1 dual agonist; LY3298176 | Development codes are distinct from approved product names |
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
December 12, 2005: Law concerning the treatment of repeat offenses. March 23, 2006: Law concerning equal pay between women and men. March 31, 2006: Law for equal opportunities. April 4, 2006: Law strengthening the prevention and repression of violence within couples or committed against minors. July 24, 2006: Law concerning immigration and integration. January 31, 2007: Law aiming to promote equal access for women and men to electoral mandates and elective functions (mandatory parity for municipalities with more than 3,500 inhabitants and in regional executives; alternates for general councilors, both of different genders; reduced public aid for a political party in case of non-compliance with parity for legislative election candidacies). This law will be followed by the laws of February 26 and July 23, 2008, concerning the facilitation of equal access between women and men to certain mandates and elected functions, as well as to social and professional responsibilities. March 5, 2007: Law concerning the prevention of delinquency. March 14, 2007: Creation of "3919," a national telephone number for victims and witnesses of domestic violence. April 13, 2007: Decree concerning the methods of calculation and sharing of family allowances in the case of alternating residence of children at each parent's home and amending the Social Security Code (second part: Decrees in the Council of State). August 1, 2007: Law authorizing the ratification of the Council of Europe Convention on Action against Trafficking in Human Beings.
On 11 August, Lula and ministers unveiled a new Growth Acceleration Programme, according to the proposal, an estimated 1.7 trillion reais (worth around US$350 billion at the time) will be spent over the following 4 years. Of this, 610 billion is expected to be spent on slum urbanisation programmes, including the development of housing, public transport, sanitation, energy and protection from natural disasters, this includes further investments on social infrastructure programmes such as Minha Casa, Minha Vida, Luz Para Todos and Água Para Todos, as well as creation and expansion of ports, airports, motorways and railways. 540 billion is expected to be spent on expanding the electric grid and petrochemical industries, with 80% of the newly developed electric production capacity being expected to come from renewable sources; 349 billion is expected to be spent on transportation infrastructure, including for motor vehicles, trains, marine vehicles, and aeroplanes. Lula also announced the construction of the "West-East Integration Railway (FIOL)" as the first project of the programme, which will connect the southwest of Bahia to the coast of southern Bahia. Other areas of investment include "digital inclusion and connectivity" (expansion of 4G and 5G networks and digital education), healthcare (construction of new basic health units and maternities, as well purchase of ambulances and vaccines), education (construction, expansion and modernization of day care centers, full-time schools and federal institutes and universities) and defence infrastructure.
=== Common PTMs by frequency === In 2011, statistics of each post-translational modification experimentally and putatively detected have been compiled using proteome-wide information from the Swiss-Prot database. The 10 most common experimentally found modifications were as follows:
Amat-Mamu (fl. c. 1736 BC) was a Babylonian nadītu priestess in Sippar from the 18th century BC who was the subject of legal proceedings involving her inheritance. Amat-Mamu was chosen as the heir of fellow nadītu Belessunu, who bequeathed Amat-Mamu her land and slaves. In exchange, Amat-Mamu was to provide for Belessunu until her death. The estate was claimed by two of Belessunu's cousins, but the mayor ruled in favor of Belessunu and Amat-Mamu. Amat-Mamu then lost the deeds when they were kept in her uncle's home, requiring her to have them reconstituted in a new tablet. This tablet was preserved, and its description of Amat-Mamu's inheritance provides insight into Babylonian inheritance practices.
Sources: en.wikipedia.org
Seeking to mend ties with the agribusiness sector, the government launched the 2023–2024 Crop Plan, providing R$ 364 billion in rural credit at interest rates below those prevailing in the financial market. This represented a 27% increase in funds compared to the 2022–2023 edition under the previous administration. The "Family Farming Harvest Plan" was also launched, which sought to strengthen family farming by extending rural credit to small and medium landowners, with around R$ 77.7 billion in resources being released for this plan in 2023-2024, a 34% increase in funding compared to the 2022–2023 edition. For the 2024–2025 edition, the government released R$ 400 billion in resources for large landowners, and R$ 85,7 billion for small and medium ones. The 2025–2026 edition released another R$ 516 billion in rural credit for large landowners, and R$ 78,2 billion for family farming. For the 2026–2027 edition, it released R$ 525.1 billion in credit for the agribusiness and another R$ 85 billion for small farms.
The left corridor had a beautiful mural showing a monk transmitting the teachings of the Buddha to a kneeling royal family, whether the mural in front of it on the external wall was entirely gone. Similarities have been noted between the paintings of the Cave of the Painters and those of Dilberjin Tepe and Penjikent of the 5th–6th centuries.
The Society holds an annual conference in late May or early June as well as topical conferences (at Asilomar State Beach in California and Sanibel Island, Florida) and a fall workshop, which is also focused on a single topic. Conferences on Mass Spectrometry and Allied Topics have been held yearly since 1953. International Mass Spectrometry Foundation List of female mass spectrometrists ASMS website
There is no specific treaty ban on the use of DU projectiles. There is a developing scientific debate and concern expressed regarding the impact of the use of such projectiles and it is possible that, in future, there will be a consensus view in international legal circles that use of such projectiles violate general principles of the law applicable to use of weapons in armed conflict. No such consensus exists at present.According to the United Nations Institute for Disarmament Research, depleted uranium does not meet the legal definitions of nuclear, radiological, toxin, chemical, poison or incendiary weapons, as far as DU ammunition is not designed nor intended to kill or wound by its chemical or radiological effects.
The iron storage disorder hereditary hemochromatosis (HHC) is an autosomal recessive genetic disorder that usually results from defects in this gene. The disease-causing genetic variant most commonly associated with hemochromatosis is p. C282Y. About 1/200 of people of Northern European origin have two copies of this variant; they, particularly males, are at high risk of developing hemochromatosis. This variant may also be one of the factors modifying Wilson's disease phenotype, making the symptoms of the disease appear earlier. Allele frequencies of HFE C282Y in ethnically diverse western European white populations are 5-14% and in North American non-Hispanic whites are 6-7%. C282Y exists as a polymorphism only in Western European white and derivative populations, although C282Y may have arisen independently in non-whites outside Europe. HFE H63D is cosmopolitan but occurs with greatest frequency in individuals of European descent. Allele frequencies of H63D in ethnically diverse western European populations are 10-29%. and in North American non-Hispanic whites are 14-15%. At least 42 mutations involving HFE introns and exons have been discovered, most of them in persons with hemochromatosis or their family members. Most of these mutations are rare. Many of the mutations cause or probably cause hemochromatosis phenotypes, often in compound heterozygosity with HFE C282Y. Other mutations are either synonymous or their effect on iron phenotypes, if any, has not been demonstrated.
Sources: en.wikipedia.org
Liquid chromatography combined with mass spectrometry is the most common approach. Digestion followed by peptide mapping verifies the sequence and modification sites. Results are judged against a reference standard or a theoretically calculated mass.
Lower temperatures slow most degradation routes, and storage at minus twenty degrees Celsius or below is standard for lyophilized material. Repeated warming and cooling imposes stress on the molecule. Dissolved samples deteriorate faster and are usually handled over shorter periods.
It normally reflects the relative chromatographic area of the principal peak. It does not capture every possible impurity or demonstrate biological function. Additional methods are required to describe a sample completely.
It is a synthetic peptide of 39 amino acids bearing a lipid side chain. Its size and architecture place it outside the small-molecule class, and laboratories generally handle it with the precautions used for biologic-like molecules.